All > Overactive Bladder

OnabotulinumtoxinA 100 UNT for Overactive Bladder

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Overactive Bladder+1 MoreOnabotulinumtoxinA 100 UNT - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial will study whether BOTOX can help treat overactive bladder symptoms during prolapse surgery.

Eligible Conditions
  • Overactive Bladder
  • Pelvic Organ Prolapse

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Similar Trials

1
IncobotulinumtoxinA
3
20 Botox Injections
3
5 mL Group

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: At 6-12 weeks postoperatively

At 6-12 weeks postoperatively
Patient Global Impression of Improvement Scale (PGI-I) at 6 to 12 weeks postoperatively.
Week 12
Urinary retention
Week 12
Change from baseline to postoperative weeks 6 to 12 in Overactive Bladder bother short form (OAB-q SF) questionnaire looking for a decrease of 10 points, which is the minimally important difference.
Change from baseline to postoperative weeks 6 to 12 in Patient Global Impression of Severity Scale (PGI-S).
Change from baseline to postoperative weeks 6 to 12 in the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire short form (PISQ-12).
Week 12
Urinary tract infection

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
IncobotulinumtoxinA
3
20 Botox Injections
3
5 mL Group

Trial Design

2 Treatment Groups

Intravesical OnabotulinumtoxinA
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

138 Total Participants · 2 Treatment Groups

Primary Treatment: OnabotulinumtoxinA 100 UNT · Has Placebo Group · Phase 4

Intravesical OnabotulinumtoxinA
Drug
Experimental Group · 1 Intervention: OnabotulinumtoxinA 100 UNT · Intervention Types: Drug
Placebo
Other
PlaceboComparator Group · 1 Intervention: Injectable saline · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: at 6-12 weeks postoperatively

Who is running the clinical trial?

Walter Reed National Military Medical CenterLead Sponsor
125 Previous Clinical Trials
35,890 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are a woman scheduled for prolapse surgery.
You have bothersome OAB symptoms.
You are willing to perform clean intermittent catheterization (CIC).
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top